Decreased serum levels of IL-4 correlate with the efficacy of the PAI-1 inhibitor TM5614 in patients with malignant melanoma refractory to anti-PD-1 antibodies: post hoc study of TM5614-MM trial.
Emi YamazakiTaku FujimuraManami Takahashi-WatanabeSatsuki TadaChisako KitayamaRyo AmagaiYumi KanbayashiMasahiro WatanabeMasamitsu MaekawaNariyasu ManoYoshihide AsanoPublished in: The British journal of dermatology (2024)
Keyphrases